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Objectives The treatment of vulvovaginal candidiasis (VVC) is still
unsatisfactory, especially in pregnant women, being promising to the
utilization of alternative therapies. Propolis extract solution (PES) has
demonstrated antifungal efficacy and low toxicity. In addition, the
subproduct of propolis extract solution (SPES) is produced during the
process of preparing PES and is usually discarded, but can still sub-
mit substances responsible for biological effects, such as the polyphe-
nols, responsible for the therapeutic activity of propolis. SPES have
not been investigated or used as an antimicrobial agent. Thus, the
objective of the present study was to investigate the effect of PES and
SPES on Candida spp. isolated from the vaginal material of pregnant
women.
Methods Vaginal samples from 291 pregnant women were collected
and cultivated for yeasts, which were identified by the classical
method and performing susceptibility tests against PES, SPES and
conventional antifungal agents. The anti-biofilm effect and cytotoxic-
ity tests of the PES and SPES were evaluated.
Results In 38.48% (112/291) of culture was positive for Candida
species. There were patients with two different species, being a total
of 115 yeasts (82.61% C. albicans; 6.08% C. glabrata; 5.22% C. tropi-
calis; 5.22% C. parapsilosis and 0.87% C. krusei). PES and SPES were
effective, even against isolates resistant to conventional antifungal
(Table 1) and reduced about 25% C. tropicalis biofilm, besides pre-
senting its low toxicity in the concentrations of fungicides.
Conclusion Thus, in addition to the PES, SPES can also be a promis-
ing alternative treatment, especially in this population.
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Objectives Candida parapsilosis has emerged as one of the most
important opportunistic pathogens, and the second most commonly
isolated Candida species from blood cultures in Latin America, Europe,
Canada and Asia. In addition, drug-resistant isolates are emerging
quickly with the increasing clinical use of conventional drug, con-
tributing to the therapeutic failure. Thus, the aim of this study was
to test the antifungal activity of essential oil from Cymbopogon nardus
(EO) against C. parapsilosis ATCC 22019 and clinical isolate.
Methods The minimal inhibitory concentration (MIC) of EO was
determined according to the protocol described by Ara!ujo et al., with
modifications. The initial concentration of EO was 2000 lg ml!1.
0.1 mL was placed in a 96-well microtiter plate containing RPMI
1640 medium. Each well was inoculated with 0.1 mL of a suspen-
sion containing 2.5x103 cfu ml!1 of yeast. Amphotericin-B and flu-
conazole were used as controls of the antifungal activity. The plates
were incubated for 48 h at 37 °C. The MIC of sample was detected
following the addition of 0.02 mL 2.0% triphenyltetrazolium chlo-
ride. The time-kill assay was performed according to Zore et al., with
modifications. In brief, Sabouraud broth medium (10 mL) containing
2.5 9 103 cfu ml!1 of C. parapsilosis and 2 9 MIC of EO were
Table 1. Minimum inhibitory concentration (MIC) values (lg ml!1)
to amphotericin B, nystatin, fluconazole, PES and SPES.
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